Literature DB >> 7834920

Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.

L J Kohler1, A F Gohara, R W Hamilton, R S Reeves.   

Abstract

This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease. This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy. Renal biopsy revealed severe glomerulonephritis with crescents, electron dense fibrillar deposits and moderate lymphocytic interstitial infiltrate. Other possible causes of rapidly progressive glomerulonephritis were investigated and ruled out. This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7834920

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

1.  Crescentic Glomerulonephritis Associated with Pulmonary Tuberculosis.

Authors:  K V Kanodia; A V Vanikar; R D Patel; K S Suthar; H L Trivedi
Journal:  J Clin Diagn Res       Date:  2016-01-01

Review 2.  The role of medications and their management in acute kidney injury.

Authors:  Bradford L McDaniel; Michael L Bentley
Journal:  Integr Pharm Res Pract       Date:  2015-05-18

3.  Fibrillary glomerulonephritis presenting as crescentic glomerulonephritis.

Authors:  H H Shah; J Thakkar; J M Pullman; A T Mathew
Journal:  Indian J Nephrol       Date:  2017 Mar-Apr

4.  Mesangiocapillary glomerulonephritis complicating pulmonary tuberculosis.

Authors:  Paul Torpiano; Stephen Holwill; David Pace
Journal:  CEN Case Rep       Date:  2021-07-14

5.  Discovering disease-disease associations by fusing systems-level molecular data.

Authors:  Marinka Žitnik; Vuk Janjić; Chris Larminie; Blaž Zupan; Nataša Pržulj
Journal:  Sci Rep       Date:  2013-11-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.